跳至主要内容
临床试验/ACTRN12615001280594
ACTRN12615001280594招募中不适用

First-in-human study for ultrasound based endovascular carotid body ablation in subjects with treatment-resistant hypertension: a safety and feasibility study.

Cibiem Australia Pty Ltd0 个研究点目标入组 45 人开始时间: 2015年11月24日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Mean daytime systolic ABPM equal or greater than 135 mmHg during screen-in period
  • Adherent to a stable drug regimen of three (3) or more anti-hypertensive medications of different classes (including one (1) diuretic, unless diuretic intolerance is documented), with no medication changes expected for at least six (6) months post-procedure
  • Willingness and able to comply with follow-up requirements
  • Signed informed consent

排除标准

  • Secondary causes of hypertension
  • Calculated eGFR smaller than 30mL/min/1.73m2
  • History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening
  • History of acute heart failure, congestive heart failure (NYHA class III-IV), myocardial infarction, unstable angina, coronary bypass or coronary angioplasty during six (6) months prior to screening
  • History of ipsilateral carotid endarterectomy treatment or ipsilateral carotid artery stenting
  • Life expectancy of less than 12 months due to other disease

研究者

发起方
Cibiem Australia Pty Ltd

相似试验